Detalhe da pesquisa
1.
Combined inhibition of IL1, CXCR1/2, and TGFß signaling pathways modulates in-vivo resistance to anti-VEGF treatment.
Anticancer Drugs
; 27(1): 29-40, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26473526
2.
Gα15 in early onset of pancreatic ductal adenocarcinoma.
Sci Rep
; 11(1): 14922, 2021 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290274
3.
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer.
Mol Cancer Ther
; 19(1): 247-257, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562256
4.
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.
Anticancer Res
; 38(4): 1937-1946, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29599309
5.
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
Clin Cancer Res
; 23(15): 4312-4322, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28298545
6.
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Clin Cancer Res
; 22(24): 6164-6175, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27267856
7.
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis.
Oncotarget
; 6(15): 13822-34, 2015 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25360865
8.
Toll-Like Receptor 9 Agonists for Cancer Therapy.
Biomedicines
; 2(3): 211-228, 2014 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28548068